A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

In brief

This phase 1 single ascending dose study will provide a first in human assessment of safety and tolerability of PF-06755347 in healthy adult males as well as adult males and females with Immune Thrombocytopenia (ITP). Pharmacokinetics and pharmacodynamics will also be evaluated.

Key facts

Study ID

NCT03275740

Run by

Pfizer

People needed

58

Starts

2017-07-17

Expected to finish

2023-01-06

Last updated by the study team

2024-07-05

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

Where it is running

• Pfizer New Haven Clinical Research Unit — New Haven, Connecticut, United States
• Pfizer Clinical Research Unit — Brussels, Belgium
• NZCR (New Zealand Clinical Research) OPCO Limited — Christchurch, New Zealand
• Hospital Universitario La Paz — Madrid, Spain
• Hospital Universitario Virgen del Rocío — Seville, Spain
• Hammersmith Medicines Research (HMR) — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.